TAK-994

TAK-994 is an experimental drug that is currently under development by Takeda Pharmaceutical Company. It is being studied for its potential use in the treatment of narcolepsy.

History[edit | edit source]

TAK-994 is based on the orexin system, which is a group of neurons in the brain that produce the neurotransmitter orexin. This system is known to play a crucial role in maintaining wakefulness and regulating the sleep-wake cycle. The drug is designed to stimulate the orexin system and thereby increase wakefulness and decrease excessive daytime sleepiness.

Clinical Trials[edit | edit source]

TAK-994 is currently in Phase 2 clinical trials. The trials are designed to evaluate the safety and efficacy of the drug in patients with narcolepsy. The primary outcome measure is the change in the Epworth Sleepiness Scale score from baseline to the end of the treatment period.

Potential Impact[edit | edit source]

If successful, TAK-994 could provide a new treatment option for patients with narcolepsy, a condition for which there is currently no cure. It could also potentially be used to treat other conditions characterized by excessive daytime sleepiness.

See Also[edit | edit source]

TAK-994 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.